euro-pathology-2017-keynote

7 / 10

Volume 7, Issue 4 (Suppl) J Clin Exp Pathol, an open access journal
ISSN: 2161-0681 Euro Pathology 2017
August 02-03, 2017
Page 48
Notes:
conferenceseries.com
13 th EUROPEAN PATHOLOGY CONGRESS
August 02-03, 2017 Milan, Italy
Reinhard Buettner, J Clin Exp Pathol 2017, 7:4(Suppl)
DOI: 10.4172/2161-0681-C1-036
Experiences from the Network of Genomic Medicine (NGM)
Traditionally, tumors are classified by histopathological criteria, i.e., based on their specific morphological appearances.
Consequently, current therapeutic decisions in oncology are strongly influenced by histology rather than underlying molecular
or genomic aberrations. The increase of information onmolecular changes however, enabled by the Human Genome Project and the
International Cancer Genome Consortium as well as the manifold advances in molecular biology and high-throughput sequencing
techniques, inaugurated the integration of genomic information into disease classification. We have therefore introduced multiplex
deep sequencing of informative gene sets into routine histopathological diagnostics and molecular pathology. This comprehensive
approach integratingmorphological andmolecular information is currently changing cancer diagnostics infive categories: (1) Somatic
genomic or epigenomic alterations acquired during cancerogenesis may be used for disease classification as we show this approach
adding important information to conventional morphological classifications. (2) A significant portion of solid tumors depend on
oncogenic driver lesions, which provide molecular targets for prediction of effective and selective therapies. (3) Genomic alterations
in signal transduction cascades and gene expression pattern may be used as prognostic parameters predicting the need and extent
of adjuvant therapy. (4) In the case of multiple syn- or metachronous tumors, genomic profiling assists allocation of metastases from
tumors with unknown primary (CUP) and correct staging as multiple small primary tumors and systemic metastases are reliable
being discriminated. (5) Finally, mutational profiling of tumor circulating tumor DNA may facilitate monitoring the response of
tumors to therapy and development of secondary resistance.
Taken together, comprehensivemolecular tumorpathologyandoncologypaves theway for anewrational and thebasis of personalized
genomic medicine. This requires state-of-the art tumor diagnostics and therapies in an interdisciplinary approach. Therefore, we will
eview current technology and applications of NGS for molecular and predictive cancer diagnostics.
Biography
Reinhard Büttner is Professor and Chairman of The Institute of Pathology at University Hospital Cologne, Köln, Germany, and the Co-Founder and Chief Scientific Officer
of TARGOS Molecular Diagnostics. He completed his medical degree at the University of Mainz, Mainz, Germany, in 1985, before starting a residency at Rheinisch-West-
falische Technische Hochschule RWTH Aachen, Aachen, Germany. In 1987, he began post-doctoral work at the Gene Centre Munich and MD Anderson Cancer Centre,
Houston, TX, USA (1987-1990). Returning to Germany in 1991, he took up a residency at the University of Regensburg, before becoming Professor and Chairman for
Pathology at RWTHAachen (1999-2001).After which, he worked as a Professor and Chairman of Pathology at the University of Bonn (2001-2011), before being appointed
to his current position as Professor and Chairman of Pathology at the University of Cologne in 2011.
Reinhard Buettner
University Hospital Cologne,Germany